ATX Insider Trading

Insider Ownership Percentage: 21.08%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Amplia Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Amplia Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amplia Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for ATX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
CLICK HERE TO FIND OUT MORE

Amplia Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/31/2023Robert PeachInsiderExpiry480,000A$0.09A$42,240.00
8/29/2023Christopher BurnsInsiderIssued2,500,000A$0.09A$220,000.00
9/6/2022Christopher BurnsInsiderIssued535,000A$0.10A$53,500.00
8/3/2022Warwick TongInsiderBuy161,107A$0.10A$15,949.59
2/10/2022S Jane BellInsiderBuy127,136A$0.17A$21,613.12
12/20/2021S Jane BellInsiderBuy714,285A$0.15A$103,571.33
9/2/2021Jane BellInsiderBuy557,646A$0.21A$115,432.72
6/7/2021John LambertInsiderExercise130,000A$0.16A$20,150.00
See Full Table
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
CLICK HERE TO FIND OUT MORE

SEC Filings (Institutional Ownership Changes) for Amplia Therapeutics (ASX:ATX)

23.14% of Amplia Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Read More on Amplia Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

77,249 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Who are the company insiders with the largest holdings of Amplia Therapeutics?

Amplia Therapeutics' top insider investors include:
  1. Christopher Burns (Insider)
  2. Robert Peach (Insider)
  3. Warwick Tong (Insider)
Learn More about top insider investors at Amplia Therapeutics.